Diagnosis of Hypertrophic Cardiomyopathy: What Every Cardiologist Needs to Know Diagnosis of Hypertrophic Cardiomyopathy: What Every Cardiologist Needs to Know
Although it is the most common inherited monogenic cardiac disorder, affecting up to 0.5% of the population, there is a gap in the recognition of this condition.ACC.org (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - May 22, 2020 Category: Cardiology Tags: Cardiology Article Source Type: news
Functional Gains From Novel Agent for OHCM, Top-line Results Functional Gains From Novel Agent for OHCM, Top-line Results
Patients with obstructive hypertrophic cardiomyopathy showed consistent hemodynamic and functional gains on mavacamten, which targets cardiac myosin, in top-line results released by MyoKardia.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - May 12, 2020 Category: Cardiology Tags: Cardiology News Source Type: news
Peninsula heart drug maker soars on positive late-stage clinical trial
Aiming to ask regulators early next year to approve its treatment for a potentially fatal heart condition, a Peninsula company's stock jumped more than 70% today on news that its drug passed a critical late-stage clinical trial.
MyoKardia Inc. (NASDAQ: MYOK) of Brisbane said early data from a 251-patient, Phase III clinical trial indicates that people with a heart condition known as symptomatic, obstructive hypertrophic cardiomyopathy, or HCM, who were given the drug mavacamten over 30 weeks saw… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - May 11, 2020 Category: Biotechnology Authors: Ron Leuty Source Type: news
Peninsula heart drug maker soars on positive late-stage clinical trial
Aiming to ask regulators early next year to approve its treatment for a potentially fatal heart condition, a Peninsula company's stock jumped more than 70% today on news that its drug passed a critical late-stage clinical trial.
MyoKardia Inc. (NASDAQ: MYOK) of Brisbane said early data from a 251-patient, Phase III clinical trial indicates that people with a heart condition known as symptomatic, obstructive hypertrophic cardiomyopathy, or HCM, who were given the drug mavacamten over 30 weeks saw… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - May 11, 2020 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news
Connecting the dots between heart disease, potential for worse COVID-19 outcomes
(Mayo Clinic) People with certain heart diseases may be more susceptible to worse outcomes with COVID-19, but the reason why has remained unknown. New research from Mayo Clinic indicates that in patients with one specific type of heart disease ? obstructive hypertrophic cardiomyopathy (HCM) ? the heart increases production of the ACE2 RNA transcript and the translated ACE2 protein. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - April 27, 2020 Category: Infectious Diseases Source Type: news
Physicians, scientists and physician-scientists connect dots between heart disease, potential for worse COVID-19 outcomes
ROCHESTER, Minn. ? People with certain heart diseases may be more susceptible to worse outcomes with COVID-19, but the reason why has remained unknown. New research from Mayo Clinic indicates that in patients with one specific type of heart disease ? obstructive hypertrophic cardiomyopathy (HCM) ? the heart increases production of the ACE2 RNA transcript [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - April 26, 2020 Category: Databases & Libraries Source Type: news
What Causes Tachycardia?
Discussion
Tachycardia is a rapid heart rate that is above normal for age and level of exertion. Tachycardia is common, particularly sinus tachycardia due to normally encountered circumstances such as pain, fever or exercise. It is usually a normal physiologic process but sustained tachycardia often indicates a potentially abnormal underlying cause.
Sinus tachycardia has a rapid heart rate with normal P waves and P-R intervals and variations from moment to moment and respiration. Generally it is not over 200 beats/minute. Vagal stimulation can slow the heart rate; this is a gradual slowing, not an abrupt slowing seen in ...
Source: PediatricEducation.org - March 23, 2020 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news
Mayo researchers create, test AI to improve EKG testing for hypertrophic cardiomyopathy
(Mayo Clinic) An approach based on artificial intelligence (AI) may allow EKGs to be used to screen for hypertrophic cardiomyopathy in the future. With hypertrophic cardiomyopathy, the heart walls become thick and may interfere with the heart's ability to function properly. The disease also predisposes some patients to potentially fatal abnormal rhythms. Current EKG technology has limited diagnostic yield for this disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 18, 2020 Category: International Medicine & Public Health Source Type: news
AI-Enabled Stethoscope Brings Specialized Knowledge to the Point of Care
Recent results of a collaborative study between Eko and the Mayo Clinic demonstrating the use of Eko’s DUO digital stethoscope as a heart failure screening tool suggest that the device could help identify asymptomatic patients with low ejection fraction during routine physical examinations.
“The low ejection fraction algorithm was used with a very specific protocol of four touchpoints—three on the chest and one on the fingers,†said Steve Pham, MD, vice president of clinical and research affairs at Eko, in an interview with MD+DI. â&#...
Source: MDDI - December 10, 2019 Category: Medical Devices Authors: Susan Shepard Tags: Digital Health Source Type: news
Racial Differences Seen With Hypertrophic Cardiomyopathy
THURSDAY, Dec. 5, 2019 -- Racial differences in disease expression and adverse clinical outcomes exist between black and white patients with hypertrophic cardiomyopathy, according to a study published online Dec. 4 in JAMA Cardiology.
Lauren A.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 5, 2019 Category: Pharmaceuticals Source Type: news
World's most comprehensive study of a deadly heart condition yields 1st results
(University of Virginia Health System) Researchers have revealed the initial results from the world's largest comprehensive study of hypertrophic cardiomyopathy, an abnormal thickening of the heart that often goes undiagnosed and can prove deadly. The condition can present at any age, and it is the most common cause of sudden cardiac death in young athletes. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 7, 2019 Category: International Medicine & Public Health Source Type: news
Ultra-Low SCD Risk Seen in HCM Challenges Prevailing Views Ultra-Low SCD Risk Seen in HCM Challenges Prevailing Views
The risk is ' an order of magnitude lower ' and exercise less often a trigger in hypertrophic cardiomyopathy than often thought in current practice, with implications for ICDs.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 1, 2019 Category: Cardiology Tags: Cardiology News Source Type: news
Nov 1 2019 This Week in Cardiology Nov 1 2019 This Week in Cardiology
Mortality after AF ablation, cardiac rehab programs, hypertrophic cardiomyopathy, and clinician wellness are the topics Dr. John Mandrola discusses in this week ’ s podcast.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 1, 2019 Category: Cardiology Tags: Cardiology Commentary Source Type: news
AHA News: Deadly Heart Problem Might Not Be So Deadly
MONDAY, Oct. 21, 2019 (American Heart Association News) -- An incurable condition called hypertrophic cardiomyopathy may be less deadly than previously thought, according to a new study of sudden cardiac deaths among young people.
At least 1 in 500... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - October 21, 2019 Category: General Medicine Source Type: news
New Algorithm Can Help Predict Sudden-Death Risk in Kids With Hypertrophic Cardiomyopathy New Algorithm Can Help Predict Sudden-Death Risk in Kids With Hypertrophic Cardiomyopathy
Researchers have developed a new model to predict the individualized risk of sudden cardiac death (SCD) in children with hypertrophic cardiomyopathy.Reuters Health Information (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - August 27, 2019 Category: Radiology Tags: Cardiology News Source Type: news
